Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Insmed Incorporated Trends and Insights

Biotech SG&A Expenses: A Decade of Growth and Strategy

__timestampInsmed IncorporatedIntra-Cellular Therapies, Inc.
Wednesday, January 1, 20143107300010337679
Thursday, January 1, 20154321600018187286
Friday, January 1, 20165067900024758063
Sunday, January 1, 20177917100023666957
Monday, January 1, 201816821800030099855
Tuesday, January 1, 201921079600064947625
Wednesday, January 1, 2020203613000186363444
Friday, January 1, 2021234273000272611040
Saturday, January 1, 2022265784000358782000
Sunday, January 1, 2023344501000409864000
Loading chart...

Infusing magic into the data realm

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Insmed Incorporated from 2014 to 2023. Over this period, Intra-Cellular Therapies, Inc. saw a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. Meanwhile, Insmed Incorporated's expenses rose by approximately 11 times.

Key Insights

By 2023, Intra-Cellular Therapies, Inc.'s SG&A expenses surpassed Insmed Incorporated's by about 19%. This trend highlights the aggressive expansion and operational scaling of Intra-Cellular Therapies, Inc. compared to its peer. Investors and stakeholders should consider these trends when evaluating the financial health and strategic direction of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025